Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion.
Transfusion-associated graft-versus-host disease (TA-GVHD) is well recognized as an uncommon, but frequently fatal, adverse effect of blood component therapy. In this disorder, viable donor lymphocytes transfused to a vulnerable patient orchestrate a devastating attack on the recipient's tissues. In contrast to the striking reduction in infectious risks of blood transfusion, a significant residual risk of TA-GVHD remains. This article reviews the pathogenesis and mechanism of TA-GVHD, which provide the foundation for a prevention strategy. A review of selected recent cases illustrates the challenges faced in the identification, prevention, and treatment of this frustrating disorder.
Higgins
Martha J
MJ
Department of Pathology, St. John Hospital and Medical Center, Detroit, MI 48236, USA. martha.higgins@stjohn.org
Blackall
Douglas P
DP
D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D017710:Lymphocyte Transfusion / Q000009:adverse effects*